STC's Principal Activity is the reviewing potential acquisition opportunities.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-84.37%|
|vs ASX 200 (1yr)||-27.97%|
|ASX Rank||2404 of 2,560|
|Sector Rank||201 of 204|
Sinetech Limited (STC, formerly The Gruden Group Ltd) is a technology provider offering fully integrated fintech platforms in the digital marketplace, with over 100 staff, across five office locations. The Company is made up of Sinetech Digital Services, Sinetech Performance Marketing, Sinetech mobileDEN and Sinetech Government.
Incorporated Incorporated on 14 June 2007 in Western Australia.
|Auditor||UHY Haines Norton|
|Date Listed||15 Jan 2008|
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Daniel Coletta||Joint Company Secretary,Non-Executive Director||Dec 2020||
Mr Daniel Coletta
Joint Company Secretary,Non-Executive Director
Mr Coletta has experience in accounting and compliance.
|Mr Warren Leslie Barry||Non-Executive Director||Aug 2020||
Mr Warren Leslie Barry
Mr Barry has over 20 years of digital marketing experience and was the Managing Director and founder of Blackglass(2005) which is a fully integrated digital marketing business. Mr Barry has been actively involved in taking two companies to listing on the ASX. Mr Barry ran one of Australia's largest digital agencies (Patts Digital) from 2001-2005 which provided him the opportunity to work with some of Australia's leading brands
|Mr Derek Hall||Non-Executive Director,Company Secretary||Dec 2019||
Mr Derek Hall
Non-Executive Director,Company Secretary
Mr Hall is a finance and compliance specialist in the listed space. Mr Hall has commercial experience identifying key business drivers and bringing cost control and process improvement into sharp focus. Mr Hall has been involved as a Chief Financial Officer and Company Secretary for a number of publicly listed and unlisted companies involving transactions in technology, mining, oil and gas and construction.
|Mr Terence (Terry) James Butler||Non-Executive Director||Jun 2017||
Mr Terence (Terry) James Butler
Mr Butler was a co-founder of Blackglass. His career, spanning 45 years, includes executive and senior management positions in industry, and twenty five years service with the Royal Australian Navy. He has been the recipient of two Australian Defence Force Commendations for professionalism, performance and service, and during his service years achieved the rank of Senior Office. Mr Butler is Managing Director and founder of ENRAMS Australia Pty Ltd. Prior to starting this company in 2009, he held directorships and executive positions in defence and aerospace, biotech, business process outsourcing, online services, environmental engineering and programme management organisations.
|Dr Paul Bello||Joint Company Secretary||Oct 2008|
|Mr Giorgio Reggiani||Company Secretary||Feb 2008|
|Mr Harry Karelis||Non-Executive Director||N/A||
Mr Harry Karelis
|Mr Leslie Harold Webb||Non-Executive Director||N/A||
Mr Leslie Harold Webb
Mr Webb was establishing ITV Consulting Pty Limited, a corporate advisory and investment consulting business. He is also a Non-executive Director of pharmaceutical company Generic Health Limited and health insurance company iSelect. He previously sat on the Board of the ASX listed Gradipore Ltd (now Life Therapeutics).
|Mr David Dodd||Chairman||N/A||
Mr David Dodd
Mr Dodd's experience includes management and corporate development experience in the life sciences industry. Prior to joining the Stem Cell Sciences, he was President, Chief Executive Officer and Director of NASDAQ quoted Serologicals Corporation until it was acquired by Millipore Corporation on 14 July 2006. From August 1995 until June 2000, he served as President and Chief Executive Officer of Solvay Pharmaceuticals Inc. and as a member of the Management Board for the Pharmaceutical Sector for Solvay SA. He was also Chairman of the Board of Unimed Pharmaceuticals Inc., a subsidiary of Solvay Pharmaceuticals. Prior to joining Solvay, he served in a number of management and executive positions with life science corporations, including Wyeth, Bristol-Myers Squibb, and Abbott Laboratories. He was awarded the 2005 GBP Biomedical Industry Growth Award for his efforts in promoting Georgia's life sciences industry. In addition, he received the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group, in recognition of his ongoing leadership in fostering business relationships between the USA and the United Kingdom. David is also currently serving on the board of directors of Stheno Corporation, a private life sciences instrument company, as Non-executive Director; as Chairman of the Board of the American Foundation for Suicide Prevention; and, as Immediate Past-Chair, the Georgia Biomedical Partnership, and the biotechnology trade association in the State of Georgia. He was appointed President, CEO and Chairman of Bioreliance Corporation on 3 December 2007.
|Dr Peter Mountford||Non-Executive Director||N/A||
Dr Peter Mountford
Dr Mountford is currently a Director of all the companies within Stem Cell Sciences, as well as of the private company Secure Sciences Pty Ltd.
|Dr Michael (Mike) Dexter||Non-Executive Director||N/A||
Dr Michael (Mike) Dexter
Dr Dexter spent the five years prior to joining Stem Cell Sciences as Director (Chief Executive Officer) of The Wellcome Trust. During his time at The Wellcome Trust, he oversaw one of the biggest advances in biomedical research when it was announced that the human genome had been sequenced - giving scientists a detailed map of the body's make-up for the first time. Prior to joining The Wellcome Trust, he was Director of Research at the Paterson Institute for Cancer Research, Christie Hospital, NHS Trust, Manchester. He is a Fellow of the Royal Society (London), was appointed Professor of Experimental Oncology at the University of Manchester and is an honorary Fellow of the Royal College of Physicians and a founding fellow of the Academy of Medical Sciences. He is currently Chairman of the International Centre for Life, Newcastle, and the Cockcroft Institute for Accelerator Sciences in Daresbury, Cheshire. He was previously a Director of Catalyst Biomedica Ltd, the translational business arm of The Wellcome Trust. He has over 360 publications on his scientific work.
|Dr Alastair James Riddell||Chief Executive Officer||N/A||
Dr Alastair James Riddell
Chief Executive Officer
Dr Riddell has more than 24 years experience in this industry. He has spent time at Board level building companies, raising money and negotiating corporate deals. From 2006 to 2007, he held the position of Non-executive Chairman at Surface Therapeutics prior to its sale to Serentis in September 2007. From 2005, he was Chief Executive Officer of Paradigm Therapeutics where he achieved a trade sale to Takeda Pharmaceutical Corporation in March 2007. Prior to Paradigm, he was Chief Executive Officer of Pharmagene for seven years, during which time he listed the company on the main market of the London Stock Exchange. He has also held senior positions with Celltech, Centocor and Amersham International in clinical development before moving to sales and marketing. He began his professional career as a medical doctor with six years, experience in a variety of hospital specialties and in general practice. He is an active Board member of the BIA, a position he has held from 2000 to 2006 and recently re-elected to serve for the 2008 term. In November 2007, he joined the Board of Sareum Holdings plc as Non-executive Director.
|Paul Bello||Joint Company Secretary||N/A|
STC directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|30/12/19||Terence (Terry) Butler||Cancelled||19,125,375||$0.003||$57,376||Cancellation of securities|
The current holdings of STC directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Terence (Terry) Butler||30/06/2020||N/A||59,437,876||N/A||N/A|
|Michael (Mike) Dexter||N/A||N/A||N/A||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Spruson Corporation Pty Ltd||31/08/2020||71,935,828||7.10|
|BTR Holdings Pty Ltd||31/08/2020||56,488,421||5.57|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.